Two down and one yo GO!1-external Data and Safety Monitoring Board (“DSMB”) has completed its latest review of the Phase 2b part of the Company’s Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, and has provided approval for the Company to continue on with the Phase 3 part of the study.
// 2-common share purchase warrants of the Company that were issued on November 1, 2019 (the “November Warrants”), have had their expiry date accelerated to January 21, 2021.
// 3- Final results for P2b are due mid/ end of February and if good they will apply to FDA fir Emergency Used ..